Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Glen Miske

Clinical Cardiac Electrophysiology Weirton, WV Medical Doctor

NPI 1316197080 CMS profile 599167

243 Three Springs Dr Ste 5A, Ste 4, Weirton, WV 26062

Open in the dashboard

General payments

$38,731

694 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Glen Miske of Weirton, WV is reported in the CMS Open Payments database as having received $38,731 across 694 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,083 106
2024 General $3,004 134
2023 General $6,527 79
2022 General $8,545 115
2021 General $3,093 88
2020 General $8,474 64
2019 General $8,005 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Glen Miske
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Glen Miske were reported at $1,083. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Glen Miske Clinical Cardiac Electrophysiology median Middle half National median
2019 $8,005 $2,361 $585–$8,260 $163
2020 $8,474 $993 $247–$4,351 $114
2021 $3,093 $1,185 $326–$4,739 $132
2022 $8,545 $2,073 $554–$6,789 $149
2023 $6,527 $2,568 $759–$8,159 $160
2024 $3,004 $2,557 $703–$7,403 $164
2025 $1,083 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $15,063 330 payments
  2. Boston Scientific Corporation $14,536 180 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $3,963 12 payments
  4. Biotronik Inc. $1,739 26 payments
  5. Medtronic Vascular, Inc. $838 20 payments
  6. Medtronic, Inc. $569 31 payments
  7. Impulse Dynamics (USA) Inc. $496 16 payments
  8. Cardiva Medical, Inc. $317 19 payments
  9. Janssen Pharmaceuticals, Inc $213 12 payments
  10. Sanofi-Aventis U.S. LLC $173 8 payments
  11. Other $824 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,250 29 payments
  2. Food and Beverage $9,274 648 payments
  3. Consulting Fee $6,275 4 payments
  4. Travel and Lodging $5,700 10 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $1,200 1 payment
  6. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. AVEIR $4,992 41 payments
  2. Rhythmia Mapping System Diagnostic $4,750 7 payments
  3. Allure Quadra RF CRT Pacemaker $4,059 3 payments
  4. LifeVest $3,963 12 payments
  5. RHYTHMIA Diagnostic $3,146 22 payments
  6. RHYTHMIA Pain Management $2,107 15 payments
  7. General - Therapies $1,565 8 payments
  8. VANTAGEVIEW $1,383 1 payment
  9. Confirm Rx $1,110 27 payments
  10. Rhythmia Mapping System Rhythmia_EP $851 11 payments
  11. Other $9,924 558 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,429

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$452,251

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

31.9%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 315 $216,342
Xarelto Rivaroxaban Brand 156 $115,065
Dofetilide Generic 184 $45,777
Entresto Sacubitril/Valsartan Brand 37 $33,236
Amiodarone Hcl Generic 354 $8,007
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 49 $7,236
Flecainide Acetate Generic 204 $6,702
Pradaxa Dabigatran Etexilate Mesylate Brand 24 $5,933
Metoprolol Succinate Generic 403 $3,215
Mexiletine Hcl Generic 38 $1,864

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$231,210

Medicare's payments for the services billed

Medicare patients

793

Average age 77

Services billed

3,707

322 women, 471 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 70%
Ischemic heart disease 62%
Heart failure 56%
Arthritis 55%
Diabetes 41%
Chronic kidney disease 38%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $22
$22 315 —
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $6
$6 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

694 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record